Literature DB >> 29795749

Academic Drug Development: The DRIVE Model.

Dennis Liotta1, George Painter2.   

Abstract

Although there are hundreds of academic drug discovery centers open around the world, there are comparatively few academic drug development centers that contain the key core competencies needed to progress a lead compound into clinical trials. This is largely a consequence of operating in the "Valley of Death" (i.e., insufficient infrastructure, expertise, and funding). We have created an academic drug development center called DRIVE (Drug Innovation Ventures at Emory) that was designed to overcome many of the intrinsic and occasionally unintended barriers associated with academic drug development. Herein, we report a proof of concept that the DRIVE model provides a robust framework for pursuing university-based drug development, especially when the drugs in question target rare and neglected diseases.

Entities:  

Year:  2018        PMID: 29795749      PMCID: PMC5949841          DOI: 10.1021/acsmedchemlett.8b00124

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  2 in total

1.  US academic drug discovery.

Authors:  Stephen Frye; Marina Crosby; Teresa Edwards; Rudolph Juliano
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

2.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.